Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Herbert Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3950-4815; OpenAlex author ID A5074071367, A5110197532. Sources: OpenAlex.

Their work

Papers
46 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
100
Papers, trials and grants by year

2011: 3 papers · 2012: 4 papers · 2013: 6 papers · 2014: 3 papers · 2015: 8 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 6 papers · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 46

  1. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  2. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  3. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  4. Association between prediagnostic serum metabolites and pancreatic ductal adenocarcinoma risk in two prospective cohorts. Co-author DOI 10.1002/ijc.35479↗
  5. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  6. Elucidating the role of blood metabolites on pancreatic cancer risk using two-sample Mendelian randomization analysis. Co-author DOI 10.1002/ijc.34771↗
  7. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-24-0096↗
  8. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  9. Nested Case-Control Studies Investigating Serum Perfluorooctanoate and Perfluorooctane Sulfonate Levels and Pancreatic Ductal Adenocarcinoma in Two Cohorts. Co-author DOI 10.1289/ehp13208↗
  10. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  11. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  12. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  13. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  14. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  15. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0091↗
  16. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  17. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  18. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  19. Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Co-author DOI 10.1158/1055-9965.epi-18-1235↗
  20. Aspirin Use and Reduced Risk of Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-16-0508↗
  21. Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis. Co-author DOI 10.1097/mpa.0000000000000392↗
  22. Menstrual and Reproductive Factors, Hormone Use, and Risk of Pancreatic Cancer: Analysis From the International Pancreatic Cancer Case-Control Consortium (PanC… Co-author DOI 10.1097/mpa.0000000000000635↗
  23. Plasma metabolite biomarkers for the detection of pancreatic cancer. Co-author DOI 10.1021/pr501135f↗
  24. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  25. Risch et al. Respond to "Clinical Utility of Prediction Models for Rare Outcomes: The Example of Pancreatic Cancer". First author DOI 10.1093/aje/kwv025↗
  26. Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis. First author DOI 10.1093/aje/kwv026↗
  27. Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Co-author DOI 10.1093/annonc/mdv236↗
  28. Vitamin D metabolic pathway genes and pancreatic cancer risk. Co-author DOI 10.1371/journal.pone.0117574↗
  29. Urinary prostaglandin E2 metabolite and pancreatic cancer risk: case-control study in urban Shanghai. Co-author DOI 10.1371/journal.pone.0118004↗
  30. Correction: vitamin d metabolic pathway genes and pancreatic cancer risk. Co-author DOI 10.1371/journal.pone.0129983↗
  31. Variants associated with susceptibility to pancreatic cancer and melanoma do not reciprocally affect risk. Co-author DOI 10.1158/1055-9965.epi-13-0627↗
  32. Case-control study of aspirin use and risk of pancreatic cancer. First author DOI 10.1158/1055-9965.epi-13-1284↗
  33. Re-evaluation of ABO gene polymorphisms detected in a genome-wide association study and risk of pancreatic ductal adenocarcinoma in a Chinese population. Co-author DOI 10.5732/cjc.013.10060↗
  34. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Co-author DOI 10.1007/s10552-012-0078-8↗
  35. Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Co-author DOI 10.1007/s10552-012-0138-0↗
  36. ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta-analysis. Last author DOI 10.1093/aje/kws458↗
  37. Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1093/annonc/mdt336↗
  38. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. Co-author DOI 10.1371/journal.pone.0072311↗
  39. Dietary energy density is positively associated with risk of pancreatic cancer in urban Shanghai Chinese. Co-author DOI 10.3945/jn.113.178129↗
  40. Green tea drinking and risk of pancreatic cancer: a large-scale, population-based case-control study in urban Shanghai. Co-author DOI 10.1016/j.canep.2012.08.004↗
  41. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Co-author DOI 10.1093/annonc/mdr541↗
  42. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1093/annonc/mds140↗
  43. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Co-author DOI 10.1093/carcin/bgs151↗
  44. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1093/annonc/mdq613↗
  45. Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use? Co-author DOI 10.1093/annonc/mdr305↗
  46. Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. First author DOI 10.1097/mpa.0b013e31821268d1↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Harvey A. Risch Risch · 21 shared papers, 2011–2020 · strength 0.92
  2. Rachael Z. Stolzenberg‐Solomon · 5 shared papers, 2013–2025 · strength 0.61
  3. Demetrius Albanes · 3 shared papers, 2013–2025 · strength 0.49
  4. Steven C. Moore · 2 shared papers, 2023–2025 · strength 0.47
  5. Ting Zhang · 2 shared papers, 2023–2025 · strength 0.47
  6. Lingeng Lu · 8 shared papers, 2011–2017 · strength 0.42
  7. Paige M. Bracci · 10 shared papers, 2011–2020 · strength 0.37
  8. Lang Wu · 3 shared papers, 2014–2024 · strength 0.37
  9. Gloria M. Petersen · 10 shared papers, 2011–2020 · strength 0.36
  10. Steve Gallinger · 9 shared papers, 2011–2020 · strength 0.33
  11. Jingjing Zhu · 2 shared papers, 2020–2024 · strength 0.33
  12. Mark S. Kidd · 5 shared papers, 2011–2017 · strength 0.30
  13. Yu-Tang Gao · 6 shared papers, 2012–2017 · strength 0.28
  14. Stephanie J. Weinstein · 1 shared paper, 2025 · strength 0.27
  15. Hua Zhong · 1 shared paper, 2024 · strength 0.26
  16. Shuai Liu · 1 shared paper, 2024 · strength 0.26
  17. H. Bas Bueno-de-Mesquita · 9 shared papers, 2011–2016 · strength 0.25
  18. Rachel Ε. Neale · 5 shared papers, 2013–2020 · strength 0.25
  19. Eric J. Duell · 8 shared papers, 2011–2020 · strength 0.24
  20. Carlo La Vecchia · 8 shared papers, 2011–2016 · strength 0.23
  21. Donghui Li · 4 shared papers, 2016–2020 · strength 0.23
  22. Sara H. Olson · 7 shared papers, 2011–2019 · strength 0.21
  23. Robert C. Kurtz · 7 shared papers, 2011–2019 · strength 0.21
  24. Quanxing Ni · 4 shared papers, 2013–2017 · strength 0.21
  25. Mark P. Purdue · 1 shared paper, 2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.